cagrisema semaglutide cagrilintide combination trial Efficacy and safety of once-weekly cagrilintide–semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study What to Know about the

Results vary based on: Starting weight Metabolic factors Consistency with treatment Most are mild and temporary: Nausea (usually subsides in weeks) Constipation Headaches Severe side effects are rare but include pancreatitis or gallbladder issues

It is backed by third-party testing and a safe inactive ingredient profile, while product-specific testing is not currently verified by SuppCo

Patients should be screened for depression and anxiety, which commonly co-occur with obesity and may worsen during weight regain, potentially requiring mental health referral

Urban lifestyles, carbohydrate-heavy diets and sedentary habits have helped drive both conditions